Cailin Sibley, M.D., MHS, FACR

Vice President, Translational Medicine

Cailin is a rheumatologist by training with a broad background in both industry and academics (OHSU), including the NIH at NIAMS. She most recently worked for Janssen pharmaceuticals where she led the early development strategy team for rheumatologic indications, and prior to that was a leader in early clinical development in immunology at Eli Lilly. She is particularly interested in exploring novel approaches to the treatment of lupus and rheumatoid arthritis as well as mentoring of young investigators. Cailin began her academic care with a B.S. in Biology from Caltech, M.D. from the David Geffen School of Medicine at UCLA, and MHS in Health Services from Duke.